Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Pharm Sci. 2012 Aug;101(8):2635-44. doi: 10.1002/jps.23217. Epub 2012 May 24.

The potential clinical relevance of visible particles in parenteral drugs.

Author information

  • 1Pharma Development Safety Risk Management, F. Hoffmann-La Roche AG, Basel, Switzerland. lucette.doessegger@roche.com

Abstract

Visible particulates (VP) are one subclass of defects seen during the final visual inspection of parenteral products and are currently one of the top ten reasons for recalls 1,2. The risk posed by particles is still unclear with limited experience reported in humans but remains an important consideration during the manufacture and use of parenteral products. From the experimental and clinical knowledge of the distribution of particulate matter in the body, clinical complications would include events occurring around parenteral administration e.g., as a result of mechanical pulmonary artery obstruction and injection site reaction, or sub-acute or chronic events e.g., granuloma. The challenge is to better understand the implication for patients of single vials with VP and align the risk with the probabilistic detection process used by manufacturers for accept/reject decisions of individual units of product.

Copyright © 2012 Wiley Periodicals, Inc.

PMID:
22628244
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk